CPhI Online

- Biopharma News

AGC Biologics to increase capacity for pDNA and mRNA manufacturing in Heidelberg

14 Sep 2021

The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab

Global biopharmaceutical CDMO AGC Biologics has laid out plans to expand its Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

By adding an additional GMP manufacturing line, the company will boost its current 100-L and 1,000-L manufacturing capacities for a variety of different biologics projects.

The expansion includes a new GMP cleanroom for mRNA development and manufacturing, a new process development lab for microbial protein and cell and gene therapy projects, and additional warehouse capacity.

The expanded capabilities will also allow the CDMO to meet the increasing demands of the rapidly growing cell and gene therapy market.

This announcement is the latest in a series of investments AGC Biologics has made this year to expand its offerings and global footprint:

  • Last month, the company broke ground on a new multipurpose facility in Copenhagen, Denmark that will grow AGC Biologics’ global capacity.
  • Approximately one month ago, the company acquired the previously owned Novartis Gene Therapies' Longmont, CO facility, helping it to expand its cell and gene therapy capabilities footprint into the US.
  • Earlier this year, the company expanded its C> facility in Milan, Italy as well, adding additional capacity and viral vector suspension capabilities.

In a statement, AGC Biologics said it anticipates the Heidelberg facility's new capabilities will be fully operational in 2023.

Read More

Related Content